Blocked By Sublocade: Braeburn Sues To Get Brixadi Buprenorphine Formulation Onto Market

Lawsuit against US FDA challenges scope of three-year exclusivity awarded to Indivior’s Sublocade, the first monthly depot formulation of buprenorphine for treating opioid use disorder.

Road Closed

Braeburn Pharmaceuticals Inc. is challenging the breadth of three-year marketing exclusivity awarded to Indivior PLC’s Sublocade (buprenorphine extended-release), which is blocking its Brixadi buprenorphine depot injection from coming to market in the US.

In a lawsuit filed against the US Food and Drug Administration April 9, Braeburn said the exclusivity awarded to Sublocade...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet